Claims:

~~1. FMO3 inhibitor for use in the treatment of pain.~~

~~2. FMO3 inhibitor for use according to claim 1, wherein the FMO3 inhibitor is selected from Tenofovir and Methimazole.~~

~~3. FMO3 inhibitor for use according to claim 1, wherein the FMO3 inhibitor is selected from a compound comprising a phosphoric acid or ester group and/or a purine radical, the compound being Tenofovir.~~

~~4. FRK inhibitor selected from dasatinib, motesanib, Doramapimod, Pelitinib, sorafenib, Vandetanib and Canertinib for use in the treatment of pain.~~

~~5. FRK inhibitor for use according to claim 4, wherein the inhibitor is selected from compounds with a Kd of lower than 3000 nM, preferably lower than 2000 nM, especially preferred lower than 1000 nM, selected from dasatinib, motesanib, Doramapimod, Pelitinib, sorafenib and Vandetanib.~~

~~6. FRK inhibitor for use according to claim 4, wherein the inhibitor is selected from compounds comprising a substituted pyridine, quinoline, isoquinoline or pyrimidine group, selected from motesanib (AMG-706), Pelitinib (EKB-569), sorafenib (sorafenib), Vandetanib (Vandetanib) and canertinib (CI-1033).~~

~~7. FRK inhibitor for use according to claim 4 or 5, wherein the inhibitor is selected from compounds comprising a substituted aniline group with a Kd value less than 1000 nM, selected from dasatinib (dasatinib), motesanib (AMG-706), Doramapimod (BIRB 796), Pelitinib (EKB-569), sorafenib (sorafenib), Vandetanib (Vandetanib).~~

~~8. FRK inhibitor for use according to claim 4, wherein the inhibitor is selected from compounds comprising a chlor-, fluor- or chlor- and fluor- substituted aniline group selected from dasatinib, Pelitinib, sorafenib, Vandetanib and canertinib.~~

~~9. FRK inhibitor selected from compounds comprising a substituted aniline group, selected from dasatinib (dasatinib), motesanib (AMG-706), doramapimod (BIRB 796), pelitinib (EKB-569), sorafenib (sorafenib), vandetanib (vandetanib), canertinib (CI-1033) and imatinib (STI-571) for use in the treatment of neuropathic pain, preferably trigeminal neuralgia, post-herpetic neuralgia, painful diabetic neuropathy, painful diabetic peripheral neuropathy, diabetic polyneuropathy, such as sciatic pain, radiculopathy, radicular pain, non-inflammatory neuropathic pain or a combination thereof.~~

~~10. LPAR3 modulator for use in the treatment of pain.~~

~~11. LPAR3 modulator for use according to claim 10, wherein the modulator is selected from compounds comprising N6-Benzyladenosine-5'-phosphate, p-Aminobenzoly PAB-J acid, NSC161613 and NSC47091.~~

~~12. LPAR3 modulator for use according to claim 10, wherein the LPAR3 modulator is an LPAR3 inhibitor.~~

~~13. LPAR3 inhibitor for use according to claim 12, wherein the inhibitor is selected from compounds comprising p-Aminobenzoly PAB-J acid, NSC161613 and NSC47091.~~

~~14. PDE4D inhibitor selected from cilomilast, Roflumilast, Filaminast, Piclamilast, V11294, Apremilast, Arofylline, Atizoram, Catramilast, Cimpyfylline, Daxalipram, Doxofylline, drotaverin, Efloxate, Etamiphylline, Etazolate, Etofylline, Broncholytine, Irimilast, oglemilast, Choline theophyllinate, Pumafentrine, Revamilast, Ronomilast, Tofimilast, Tolafentrine, Trapidil, GW 842470 (AWD 12-281), CDP-840, YM-976, CI-1018, D-4418, Lirimilast, SCH 351591, RPL-554, IPL-455903 (HT-0712), GSK256066, Zardaverine, Vardenafil, Tetomilast, IC485, L-826,141, ONO-6126, CI-1044, MK-0873, T-2585, R1533 (MEM-1414), Ronomilast, UK-500,001, AN2728, DE-103, Tofisopam, Dextofisopam, Levotofisopam (USAN) for use in the treatment of pain.~~

~~15. PDE4D inhibitor of claim 14 comprising a 1,2-dioxy-aryl group with IC50 value of 1100 nM or less, preferably 1050 nM or~~

~~less, preferably 1000 nM or less, preferably 950 nM or less, preferably 950 nM or less, preferably 900 nM or less, for use in the treatment of pain, wherein the PDE4D inhibitor is selected from cilomilast (cilomilast), Roflumilast (Roflumilast), Filaminast (Filaminast), Piclamilast (Piclamilast), (V11294), Apremilast (CC-10004), Atizoram (CP80633), Catramilast (Catramilast), Daxalipram (Daxalipram/mesopram), drotaverin (Drotaverine), broncholytine (Glaucine Hydrobromide), oglemilast (GRC3886), Pumafentrine (Pumafentrine), Revamilast (Revamilast), Tolafentrine (Tolafentrine), (CDP-840), (RPL-554), (IPL-455903 (HT-0712)), Zardaverine (Zardaverine), Tetomilast (OPC-6535), (L-826,141), Ronomilast (ELB353), Tofisopam (Tofisopam).~~

~~16. PDE4D inhibitor of claim 14 comprising a 1,2-dioxy-aryl group substituted with an alkyl or flour-alkyl group, or 1,2-dioxy-aryl group condensed in a furan ring containing oxygen selected from cilomilast (cilomilast), Roflumilast (Roflumilast), Filaminast (Filaminast), Piclamilast (Piclamilast), (V11294), Apremilast (CC-10004), Daxalipram (Daxalipram/mesopram), drotaverin (Drotaverine), broncholytine (Glaucine Hydrobromide), oglemilast (GRC3886), Pumafentrine (Pumafentrine), Revamilast (Revamilast), Tolafentrine (Tolafentrine), (RPL-554), Zardaverine (Zardaverine), Tetomilast (OPC-6535), (L-826,141), Ronomilast (ELB353), Tofisopam (Tofisopam) for use in the treatment of pain.~~

~~17. PDE4D inhibitor of claim 14 comprising a 3,5-dichlor-pyridine group or a pyridine group that is not condensed in a 2 ring structure, selected from Roflumilast (Roflumilast), Piclamilast (Piclamilast), oglemilast (GRC3886), Revamilast (Revamilast), GW 842470 (AWD 12-281), D-4418, SCH-351591 for use in the treatment of pain.~~

~~18. PDE4D inhibitor of claim 14 comprising a quinoline, isoquinoline or pyrimidine group selected from drotaverine (Drotaverine), Pumafentrine (Pumafentrine), Tolafentrine (Tolafentrine), Trapidil (Sedanin), D-4418, SCH-351591, RPL-554, GSK256066, T-2585, Ronomilast (ELB353) for use in the treatment of pain.~~

~~19. PDE4D inhibitor of claim 14 comprising an aniline group, preferably carbonyl- or chlor-substituted aniline, selected from Apremilast (CC-10004), Arofylline (LAS31025), CI-1044, T-2585 for use in the treatment of pain.~~

~~20. PDE4D inhibitor comprising a purine ring, selected from V11294, Arofylline (LAS31025), Cimpyfylline (BRL-61063), Doxofylline (Doxofylline), Etamiphylline (Etamiphylline), Etofylline (Etofylline), Choline theophyllinate (oxtriphyllin), Theophylline (Theophylline) for the treatment of neuropathic pain, especially non-inflammatory neuropathic pain.~~

~~21. CAMK1D inhibitor selected from Bosutinib (SKI-606), Pelitinib (EKB-569), EKB-568, midostaurin (PKC-412), tozasertib (MK-0457, VX 680), SU-14813, Ruboxistaurin (LY-333531), CGP-52421, for use in the treatment of pain.~~

~~22. CAMK1D inhibitor for use according to claim 21, the inhibitor comprising a chlor-substituted aniline group and is selected from Bosutinib (SKI-606) and Pelitinib (EKB-569).~~

~~23. CAMK1D inhibitor selected from bosutinib (SKI-606), pelitinib (EKB-569), EKB-568 and CGP-52421 for use in the treatment of pain.~~

~~24. Compound comprising a quinoline or isoquinoline group, selected from Bosutinib, Pelitinib (EKB-569), drotaverin (Drotaverine), Pumafentrine (Pumafentrine), Tolafentrine (Tolafentrine), (D-4418), (SCH-351591), (RPL-554), (GSK256066), (T-2585), Ronomilast (ELB353), preferably the compound being an inhibitor of FRK, PDE4D or CAMK1D, for use in the treatment of pain, preferably neuropathic pain, more preferably non-inflammatory neuropathic pain.~~

~~25. Compound comprising a chlor-substituted aniline group, selected from dasatinib (dasatinib), Pelitinib (EKB-569), sorafenib (sorafenib), Canertinib (CI-1033), Arofylline (LAS31025), (T-2585), bosutinib (SKI-606), preferably the compound being an inhibitor of FRK, PDE4D or CAMK1D, for use in the~~

~~treatment of pain, preferably neuropathic pain, more preferably non-inflammatory neuropathic pain.~~

~~26. dasatinib (dasatinib) for use in the treatment of pain.~~
~~27. AMG-706 (motesanib) for use in the treatment of pain.~~
~~28. BIRB 796 (Doramapimod) for use in the treatment of pain.~~
~~29. EKB-569 (Pelitinib) for use in the treatment of pain.~~
~~30. sorafenib (sorafenib) for use in the treatment of pain.~~
~~31. Vandetanib (Vandetanib) for use in the treatment of pain.~~
~~32. CI-1033 (Canertinib) for use in the treatment of pain.~~
~~33. imatinib (STI-571) for use in the treatment of pain.~~
~~34. N6-Benzyladenosine-5'-phosphate for use in the treatment of pain.~~
~~35. p-Aminobenzoyl PAB-J acid for use in the treatment of pain.~~
~~36. NSC161613 for use in the treatment of pain.~~
~~37. NSC47091 for use in the treatment of pain.~~
~~38. cilomilast (cilomilast) for use in the treatment of pain.~~
~~39. Nicotinamide (Nicotinamide) for use in the treatment of pain.~~
~~40. Roflumilast (Roflumilast) for use in the treatment of pain.~~
~~41. Filaminast (Filaminast) for use in the treatment of pain.~~
~~42. Piclamilast (Piclamilast) for use in the treatment of pain.~~
~~43. V11294 for use in the treatment of pain.~~
~~44. CC-10004 (Apremilast) for use in the treatment of pain.~~
~~45. LAS31025 (Arofylline) for use in the treatment of pain.~~
~~46. CP80633 (Atizoram) for use in the treatment of pain.~~
~~47. Catramilast/Atopik (Catramilast) for use in the treatment of pain.~~
~~48. BRL-61063 (Cimpyfylline) for use in the treatment of pain.~~
~~49. Daxalipram/mesopram (Daxalipram) for use in the treatment of pain.~~
~~50. Doxofylline (Doxofylline) for use in the treatment of pain.~~
~~51. Drotaverine (drotaverin) for use in the treatment of pain.~~
~~52. Efloxate (Efloxate) for use in the treatment of pain.~~
~~53. Etamiphylline (Etamiphylline) for use in the treatment of pain.~~
~~54. Etazolate (Etazolate) for use in the treatment of pain.~~

~~55. Etofylline (Etofylline) for use in the treatment of pain.~~
~~56. Glaucine Hydrobromide (Broncholytine) for use in the treatment of pain.~~
~~57. GRC3886 (oglemilast) for use in the treatment of pain.~~
~~58. oxtriphyllin (Choline theophyllinate) for use in the treatment of pain.~~
~~59. Pumafentrine (Pumafentrine) for use in the treatment of pain.~~
~~60. Revamilast (Revamilast) for use in the treatment of pain.~~
~~61. ronomilast (ELB-353) for use in the treatment of pain.~~
~~62. Tofimilast (Tofimilast) for use in the treatment of pain.~~
~~63. Tolafentrine (Tolafentrine) for use in the treatment of pain.~~
~~64. Scoanin (Trapidil) for use in the treatment of pain.~~
~~65. GW 842470 (AWD 12-281) for use in the treatment of pain.~~
~~66. CDP-840 for use in the treatment of pain.~~
~~67. YM-976 for use in the treatment of pain.~~
~~68. CI-1018 for use in the treatment of pain.~~
~~69. D-4418 for use in the treatment of pain.~~
~~70. Lirimilast (Lirimilast) for use in the treatment of pain.~~
~~71. SCH-351591 for use in the treatment of pain.~~
~~72. RPL-554 for use in the treatment of pain.~~
~~73. IPL-455903 (HT-0712) for use in the treatment of pain.~~
~~74. GSK256066 for use in the treatment of pain.~~
~~75. Zardaverine (Zardaverine) for use in the treatment of pain.~~
~~76. Vardenafil (Vardenafil) for use in the treatment of pain.~~
~~77. OPC-6535 (Tetomilast) for use in the treatment of pain.~~
~~78. IC485 for use in the treatment of pain.~~
~~79. L-826,141 for use in the treatment of pain.~~
~~80. ONO-6126 for use in the treatment of pain.~~
~~81. CI-1044 for use in the treatment of pain.~~
~~82. MK-0873 for use in the treatment of pain.~~
~~83. T-2585 for use in the treatment of pain.~~
~~84. R1533 (MEM-1414) for use in the treatment of pain.~~
~~85. UK-500,001 for use in the treatment of pain.~~
~~86. AN2728 for use in the treatment of pain.~~
~~87. DE-103 for use in the treatment of pain.~~
~~88. Tofisopam (Tofisopam) for use in the treatment of pain.~~
~~89. (R)-Tofisopam (Dextofisopam) for use in the treatment of .~~

~~pain.~~

~~90. (S)-Tofisopam (Levotofisopam (USAN)) for use in the treatment of pain.~~

~~91. EKB-568 for use in the treatment of pain.~~

~~92. midostaurin (PKC-412) for use in the treatment of pain.~~

~~93. tozasertib (MK-0457, VX 680) for use in the treatment of pain.~~

~~94. SU-14813 for use in the treatment of pain.~~

~~95. lestaurtinib (CEP-701) for use in the treatment of pain.~~

~~96. LY-333531 (Ruboxistaurin) for use in the treatment of pain.~~

~~97. CGP-52421 for use in the treatment of pain.~~

~~98. SKI-606 (Bosutinib) for use in the treatment of pain.~~

~~99. Roscovitine (Roscovitine) for use in the treatment of pain.~~

~~100. Tenofovir (PMPA) (Tenofovir) for use in the treatment of pain.~~

~~101. Methimazole (Methimazole) for use in the treatment of pain.~~

1 ~~102~~. Remofovir (Pradefovir) for use in the treatment or prevention of pain.

2 ~~103~~. Adefovir for use in the treatment or prevention of pain.

3 ~~104~~. Adefovir for use according to claim 2 ~~103~~, characterized in that Adefovir is Adefovir dipivoxil (Bis-POM PMEA).

~~105. Acetazolamide (Acetazolamide) for use in the treatment of pain.~~

~~106. Luteolin for use in the treatment of pain.~~

~~107. Method of treating or reducing pain in a subject comprising administering a compound of any one of claims 1 to 106 to a subject suffering from pain.~~

~~108. Method of preventing pain in a subject comprising administering a compound of any one of claims 1 to 106 to a subject~~

~~suffering from pain.~~

~~109. Use of a compound, modulator or inhibitor as defined in any one of claims 1 to 106 for the manufacture of an analgesic or a medicament for the treatment of pain.~~

4 ~~110~~. Compound for ~~The method or~~ use according to ~~of~~ any one of claims 1 to 3 ~~109~~, characterized in that the compound is administered topically, enterally or parenterally, in particular preferred orally or rectally, intravenously, intraarterially, intramuscularly, subcutaneously, intradermally, intraperitoneally, transdermally, transmucosally or by inhalation.

5 ~~111~~. Compound for ~~The method or~~ use according to ~~of~~ any one of claims 1 to 4 ~~110~~, characterized in that the subject to be treated is a mammal, preferably a human.

6 ~~112~~. Compound for ~~The method or~~ use according to ~~of~~ any one of claims 1 to 5 ~~111~~, characterized in that the compound, modulator or inhibitor is provided in a medicament.

7 ~~113~~. Compound for ~~The method or~~ use according to ~~of~~ any one of claims 1 to 6 ~~112~~, characterized in that the compound, modulator or inhibitor is provided together with a pharmaceutically acceptable carrier or buffer.

8 ~~114~~. Compound for ~~The method or~~ use according to ~~of~~ any one of claims 1 to 7 ~~113~~, characterized in that the compound, modulator or inhibitor is administered in a therapeutically effective dosage, preferably a dosage of between 0.01 mg/kg and 1 g/kg.

9 ~~115~~. Compound for ~~The method or~~ use according to any one of claims 1 to 8 ~~114~~, wherein pain is selected from or associated with chronic or acute pain or hyperalgesia pain, somatogenic pain, neuropathic pain, psychogenic pain, heat induced pain, physical pain, nociception, hyperalgesia, rheumatic pain, headache, low back pain, pelvic pain, myofascial pain, vascular pain, migraine, wound associated pain, inflammatory pain, arthritic pain, diabetic pain, pain from cancer, somatic visceral

pain, fibromyalgia, postoperative pain, phantom pain, trigeminal neuralgia, post-herpetic neuralgia, painful diabetic neuropathy, painful diabetic peripheral neuropathy, diabetic polyneuropathy, sciatic pain, radiculopathy, radicular pain, lumbar pain or any combination thereof.

10 ~~116~~. Compound for ~~The method or~~ use according to claim 9 ~~115~~, wherein pain is chronic pain.

11 ~~117~~. Compound for ~~The method or~~ use according to claim 9 ~~115~~ or 10 ~~116~~, wherein pain is neuropathic pain.

12 ~~118~~. Compound for ~~The method or~~ use according to claim 9 ~~115~~, wherein pain is inflammatory pain.

13 ~~119~~. Compound for ~~The method or~~ use according to claim 9 ~~115~~, 10 ~~116~~ or 11 ~~117~~, wherein pain is non-inflammatory pain.